Venn Life Sciences Holdings PLC Change of Adviser (7348I)

TIDMVENN

RNS Number : 7348I

Venn Life Sciences Holdings PLC

11 December 2015

Venn Life Sciences Holdings Plc

("Venn Life Sciences" or the "Company")

Change of Nominated Adviser and Broker

ESM Admission

Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Davy as the Company's Nominated Adviser and Joint Broker with effect from 18 January 2016. Hybridan will continue as Joint Broker to the Company.

The Company will also apply for its shares to be traded on the Irish Stock Exchange's Enterprises Securities Market (ESM), alongside its existing AIM listing. Davy will act as ESM Adviser to the Company from ESM admission, scheduled to occur on 18 January 2016.

Commenting, Venn CEO, Tony Richardson said: "We're very pleased to be working with the team at Davy and we look forward to the benefits that the dual-trading facilities of AIM and ESM offers us, particularly at a time of strong growth and our move into profitability. We look forward to actively engaging with the wider audience that the ESM offers us particularly those Eurozone investors that will be attracted to the addition of a euro denominated quotation."

 
 Venn Life Sciences Holdings Plc                                      www.vennlifesciences.com 
 Tony Richardson, Chief Executive Officer                                 Tel: [phone] 
 Jonathan Hartshorn, Chief Financial Officer                              Tel: [phone] 
 
 Davy (Nominated Adviser, ESM Adviser and                                 Tel: [phone] 
  Joint Broker(4) ) 
 Fergal Meegan / Matthew DeVere White (Corporate 
  Finance) 
 Paul Burke (Corporate Broking) 
 
 Hybridan LLP (Joint Broker)                                                Tel: [phone] 
 Claire Louise Noyce 
 
 Walbrook PR Ltd                                     Tel: [phone] or [e-mail] 
 Paul McManus                                                               Mob: [phone] 
 Lianne Cawthorne                                                           Mob: [phone] 
 
 

About Venn Life Sciences:

Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn Life Sciences specialises in rapid deployment and management of multisite projects. Venn Life Sciences also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

For more information about the Company, please visit: www.vennlifesciences.com

About Davy:

Established in 1926, the Davy Group, is Ireland's leading provider of capital markets, financial advisory and wealth & asset management services. Davy is headquartered in Dublin, with offices in London, Belfast, Cork and Galway. Employing over 610 people, Davy offers a broad range of services to corporations, small businesses, private clients and institutional investors, and organise our activities around four interrelated business areas - Capital Markets, Corporate Finance, Research, and Wealth & Asset Management.

As the leading broker in the Irish market, Davy accounted for over 43% of all dealings in Irish equities on the Irish Stock Exchange in 2014(1) . Davy is a primary dealer in Irish Government Bonds and acts as manager on the majority of Irish corporate bond issues. Davy advises 65% of companies on the Irish Stock Exchange(2) . On 8 December 2015 Davy Corporate Finance was the recipient of 'Financial Adviser of the Year - Ireland' Award for 2015 at the annual Mergermarket European M&A Awards. Davy is Ireland's leading ESM and AIM adviser, representing approximately 74% of companies quoted on the ESM market(2) , and 17 companies quoted on the AIM market of the London Stock Exchange(3) . Davy is responsible for over 70% of funds raised on the Irish Stock Exchange over the past four years(1) and is consistently recognised by the world's top names in financial services for the quality of research and service.

(1) Source: Irish Stock Exchange, December 2014

(2) Source: Irish Stock Exchange, December 2015

(3) Source: London Stock Exchange, December 2015

(4) effective from 18 January 2016

For more information about the Company, please visit: www.davy.ie

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPBBLLFELFBFBD

(END) Dow Jones Newswires

December 11, 2015 02:00 ET (07:00 GMT)